First line therapy in locally advanced or metastatic NSCLC in Asian patients
Provide Superior efficacy in EGFR mutation positive patients
As second line therapy in locally advanced or metastatic NSCLC
As maintenance therapy after first line chemotherapy in patients affected by advanced NSCL